Peter Attia vs. Peptides: A Doctor Responds
Dr. Alex Tatem — Peter Attia vs. Peptides: A Doctor Responds
Channel: Dr. Alex Tatem · Our label: Clinician; paid clinician face of Superpower (disclosed) · Source: youtube.com/watch?v=raPPwAt9ZJg
What this video covers
Peteria hates peptides and we’ve got to talk about it. Medicine 3.0, is back from the dead and apparently has a bone to pick with peptides. Now, I’m mostly kidding about the being dead part. Peter definitely took a hiatus from the public eye after the whole being best friends and physician to the Mr.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- And I think it’s important to set the record straight because Peter repeats verbatim a lot of the halftruths and mischaracterizations I saw the FDA and peptide opponents levy against these compounds firsthand.
- FDCA505D, a compound must have substantial evidence of effectiveness plus adequate safety data.
- So, let’s look at how peptides like BPC57 stack up.
- The FDA argued that we shouldn’t consider a peptide that had clinical trials in humans showing safety and efficacy because we still have FDA approved options.
- And so when someone sits there and says that we shouldn’t consider a peptide with an incredibly good safe profile that’s been characterized in humans because we have FDA approved options that kill people every single year.
- We have a study looking at the safety of IVBc BPC safety and efficacy when placed in the bladder for interstitial cyitis and another showing safety when used as an intraarticular injection with chronic knee pain and arthritis.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.